Healthcare
Nicox Announces Extension of Cash Runway
Press Release Nicox Announces Extension of Cash Runway Cash position, of €8.4 million1 as of 31 August 2026, sufficient to fund existing operations beyond Q1 2028NCX 470 U.S. NDA approval milestone would fund operations into 2029, while subsequent royalties could extend the cash runway substantially further Discussions on future strategic opportunities continuing September 2, 2026 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an internatio
About this update from Nicox Sa
1 Unaudited estimate prepared by management based on information available as of the date of this press release. The Company's next reporting will be the first half 2026 accounts in October 2026. 2 A PDUFA date is the target date by which the U.S. Food and Drug Administration (FDA) aims to complete its review and issue a decision on a New Drug Application (NDA) under the Prescription Drug User Fee Act (PDUFA). Attachment